Resverlogix Corp

Resverlogix Corp. is a late-stage clinical biotechnology company dedicated to improving the lives of patients with chronic illnesses. We provide novel science, clinical and value-based health solutions to key stakeholders such as pharmaceutical, physician, and health payer groups. In 2005, Resverlogix commenced trading on the TSX under the symbol RVX. Resverlogix is a pioneer in the landscape of epigenetics. Today, apabetalone discovered in 2006 is the world leader in a new class of drugs designed to regulate gene expression through the inhibition of bromodomain and extraterminal domain (BET) proteins. Through this mechanism, we believe we can improve the lives of...

Cardiovascular disease,atherosclerosis,neurodegenerative diseases,diabetes mellitus,chronic kidney disease,drug development,epigenetics,drug discovery,and muscular dystrophy

Resverlogix corp operates in the Biotechnology industry.

Resverlogix corp's revenue is 11m - 100m

Resverlogix corp has 11 - 50 employees.